Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a specialty pharmaceutical company, today reported unaudited consolidated financial results for the quarter ended March 31, 2013. Total revenues for the first quarter of 2013 were $17.9 million, 16 percent greater than the first quarter of 2012, driven by increased Feraheme® (ferumoxytol) U.S. sales. As of March 31, 2013, the company’s cash, cash equivalents and investments totaled approximately $217 million.
Help employers find you! Check out all the jobs and post your resume.
